Folotyn for Non-Hodgkin's Lymphoma Hagerstown MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Hind Hamdan, MD
(301) 797-8279
1130 Opal Ct
Hagerstown, MD
Specialties
Oncology (Cancer), Internal Medicine
Gender
Female
Languages
Arabic
Education
Medical School: American Univ Of Beirut, Fac Of Med, Beirut, Lebanon
Graduation Year: 1985
Hospital
Hospital: Washington County Hospital, Hagerstown, Md

Data Provided by:
Alida Mercedes Espinoza
(301) 797-8279
1130 Opal Ct
Hagerstown, MD
Specialty
Hematology / Oncology

Data Provided by:
Frederic Henry Kass III, MD
(301) 733-8607
11110 Medical Campus Rd Ste 130
Hagerstown, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1974

Data Provided by:
Michael J McCormack
(301) 733-8600
11110 Medical Campus Rd
Hagerstown, MD
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Robert Kent Finley
(717) 762-7155
45 Roadside Ave
Waynesboro, PA
Specialty
General Surgery, Surgical Oncology

Data Provided by:
Dr.Hind Hamdan
(301) 797-8279
1130 Opal Court
Hagerstown, MD
Gender
F
Education
Medical School: American Univ Of Beirut, Fac Of Med, Beirut
Year of Graduation: 1985
Speciality
Oncologist
General Information
Hospital: Washington County Hospital, Hagerstown, Md
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 3, reviews.

Data Provided by:
Michael Joseph Mc Cormack, MD
(301) 733-8600
11110 Medical Campus Rd Ste 130
Hagerstown, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1982

Data Provided by:
Dan Roger Cornell, MD
(301) 665-4650
11110 Medical Campus Rd Ste 129
Hagerstown, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Md Sch Of Med, Baltimore Md 21201
Graduation Year: 1987

Data Provided by:
Gerald Stephen Brown, MD
(301) 824-3343
22911 Jefferson Blvd
Smithsburg, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Ottawa, Fac Of Med, Ottawa, Ont, Canada
Graduation Year: 1963

Data Provided by:
Matthew Page Jones, MD
2000 Foundation Way Ste 3700
Martinsburg, WV
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Va Sch Of Med, Charlottesville Va 22908
Graduation Year: 1990

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com